ctDNA Increase May Predict Regorafenib Response in Advanced CRC

In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.

Related Content:

American Association for Cancer Research Annual Meeting (AACR)Colorectal CancerGastrointestinal Cancer

Thomas Marron, MD, PhD, on Research Design for the Neoantigen Peptide Vaccine, PGV-001

Complete Pathological Responses Seen for Resectable HCC Treated With Neoadjuvant Cemiplimab

Clinically Significant Improvement Observed With D-0316 for Subset of Patients with T790M+ and EGFR+ NSCLC